Compounds according to Formula (I) and Formula (II) are potent inhibitors of PSMA. (I) or (II) Pharmaceutical compositions may include a complex of a radionuclide and a Formula (I) compound or a Formula (II) compound. Methods include using the radionuclide complex of a Formula (I) compound or a Formula (II) compound for treating or diagnosis of a disease or a condition associated with PSMA activity.
根据公式(I)和公式(II),化合物是
PSMA的强效
抑制剂。 (I)或(II)药物组合物可以包括放射性核素和公式(I)化合物或公式(II)化合物的复合物。方法包括使用公式(I)化合物或公式(II)化合物的放射性核素复合物用于治疗或诊断与
PSMA活性相关的疾病或状况。